



(12) Translation of
European patent specification

(11) NO/EP 3463328 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/192 (2006.01)
A61P 1/16 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.08.22
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.06.15
(86)	European Application Nr.	17722943.2
(86)	European Filing Date	2017.04.26
(87)	The European Application's Publication Date	2019.04.10
(30)	Priority	2016.05.31, US, 201662343688 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560, USA
(72)	Inventor	BOUDES, Pol, c/o CymaBay Therapeutics, Inc. 7575 Gateway Boulevard Suite 110, Newark, CA 94560, USA MCWHERTER, Charles, A., c/o CymaBay Therapeutics, Inc. 7575 Gateway Boulevard Suite 110, Newark, CA 94560, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
(56)	References Cited:	WO-A1-2015/143178

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3463328

1

Patentkrav

- 5 **1.** Forbindelse som er seladelpar eller et salt derav, for anvendelse i behandling av primær biliær kolangitt, der forbindelsen administreres oralt i en dose på 5 - 10 mg daglig når dosen beregnes som seladelpar.
- 2.** Forbindelsen for anvendelse ifølge krav 1, der forbindelsen er seladelpar-L-lysin dihydratsalt.
- 10 **3.** Forbindelsen for anvendelse ifølge krav 1 eller 2, der forbindelsen administreres i en dose på 5 mg daglig.
- 4.** Forbindelsen for anvendelse ifølge krav 1 eller 2, der forbindelsen administreres i en dose på 10 mg daglig.
- 15 **5.** Forbindelsen for anvendelse ifølge et av kravene 1 til 4, der forbindelsen administreres én gang daglig.